eCite Digital Repository

Management of secondary poor response to botulinum toxin in cervical dystonia: a multicenter audit

Citation

Tucker, H and Osei-Poku, F and Ashton, D and Lally, R and Jesuthasan, A and Latorre, A and Bhatia, KP and Alty, JE and Kobylecki, C, Management of secondary poor response to botulinum toxin in cervical dystonia: a multicenter audit, Movement Disorders Clinical Practice, 8, (4) pp. 541-545. ISSN 2330-1619 (2021) [Refereed Article]


Preview
PDF (Online first)
330Kb
  

Copyright Statement

2021 The Authors. This article is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) License, (https://creativecommons.org/licenses/by/4.0/), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

DOI: doi:10.1002/mdc3.13181

Abstract

Background

Botulinum toxin A (BoNT‐A) is an effective treatment for cervical dystonia. Nevertheless, up to 30% to 40% patients discontinue treatment, often because of poor response. The British Neurotoxin Network (BNN) recently published guidelines on the management of poor response to BoNT‐A in cervical dystonia, but adherence to these guidelines has not yet been assessed.

Objectives

To assess adherence to and usefulness of BNN guidelines in clinical practice.

Methods

We undertook a retrospective medical notes audit of adherence to the BNN guidelines in 3 United Kingdom tertiary neurosciences centers.

Results

Of 76 patients identified with poor response, 42 (55%) had a suboptimal response and, following BNN recommendations, 25 of them (60%) responded to adjustments in BoNT dose, muscle selection or injection technique. Of the remaining 34 (45%) patients with no BoNT response, 20 (59%) were tested for immune resistance, 8 (40%) of whom showed resistance. Fourteen (18%) of all patients were switched to BoNT‐B, and 27 (36%) were referred for deep brain stimulation surgery. In those not immune to BoNT‐A, clinical improvement was seen in 5 (41%) after adjusting their dose and injection technique.

Conclusion

Our audit shows that optimizing BoNT dose or injection strategy largely led to improvements in those with suboptimal response and in those reporting no response without resistance. It would be helpful to standardize investigations of potential resistance in those with no therapeutic response.

Item Details

Item Type:Refereed Article
Keywords:dystonia, botulinum toxin, neurology, management, clinical
Research Division:Biomedical and Clinical Sciences
Research Group:Clinical sciences
Research Field:Clinical sciences not elsewhere classified
Objective Division:Health
Objective Group:Clinical health
Objective Field:Treatment of human diseases and conditions
UTAS Author:Alty, JE (Dr Jane Alty)
ID Code:144164
Year Published:2021
Deposited By:Wicking Dementia Research and Education Centre
Deposited On:2021-04-27
Last Modified:2021-09-22
Downloads:2 View Download Statistics

Repository Staff Only: item control page